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ABSTRACT
Chemically modified siRNAs are expected to have
resistance toward nuclease degradation and good
thermal stability in duplex formation for in vivo ap-
plications. We have recently found that 20-OMe-40
-thioRNA, a hybrid chemical modification based on
20-OMeRNA and 40-thioRNA, has high hybridization
affinity for complementary RNA and significant
resistance toward degradation in human plasma.
These results prompted us to develop chemically
modified siRNAs using 20-OMe-40-thioribonucleo
sides for therapeutic application. Effective modifica-
tion patterns were screened with a luciferase
reporter assay. The best modification pattern of
siRNA, which conferred duration of the gene-
silencing effect without loss of RNAi activity, was
identified. Quantification of the remaining siRNA in
HeLa-luc cells using a Heat-in-Triton (HIT) qRT–PCR
revealed that the intracellular stability of the siRNA
modified with 20-OMe-40-thioribonucleosides contri
buted significantly to the duration of its RNAi
activity.
INTRODUCTION
Since its discovery in 1998 (1), RNAi has rapidly become a
standard method for the investigation of gene function in
various eukaryotic cells. However, long dsRNA (>30nt)
has the potential to elicit severe innate immune response
when introduced in mammalian cells. A few years after the
discovery of RNAi, Elbashir et al. reported that exogen-
ously introduced siRNAs, 21- to 23-mers in length, could
achieve sequence-speciﬁc gene-silencing in mammalian cell
lines without sequence nonspeciﬁc silencing arising from
interferon (IFN) response (2). Owing to its potency, target
speciﬁcity and ability to silence virtually any gene, this
procedure applying siRNAs has been used not only as a
genetic tool but also as an aid in identifying new drug
candidates. However, despite these advantages, questions
concerning poor nuclease resistance in biological ﬂuids
and off-target effects (3), among others, still need to be
addressed. In addition, recent studies have shown that
even a standard 21-mer siRNA has the potential to
induce severe innate immune response in vivo (4). In
order to overcome these problems, chemical modiﬁcations
on the sugar, the phosphate backbone or the nucleobase
moiety of siRNAs have been attempted (5). A variety of
chemically modiﬁed nucleosides, such as 20-O-methyl
(20-OMe) (6–8) and 20-ﬂuoro (20-F) (9–11) substitutions,
have been used to improve the nuclease and thermal
stability of siRNA. These chemical modiﬁcations, in par-
ticular the use of 20-OMe derivatives, have also been
shown to prevent innate immune response. Recently,
Judge et al. reported that incorporation of as few as two
20-OMe guanosine and uridine residues in a highly
immunostimulatory siRNA sequence is sufﬁcient to
abrogate siRNA-mediated IFN and inﬂammatory
cytokine induction without disrupting its gene-silencing
effect in human peripheral blood mononuclear cells and
in mice in vivo (12).
On the other hand, our group (13,14) and others (15,16)
have studied siRNAs modiﬁed with 40-thionucleoside de-
rivatives. We have recently published a detailed study on
the modiﬁcation pattern–siRNA activity relationship of
siRNAs modiﬁed with 40-thioribonucleosides against the
photinus luciferase and renilla luciferase genes in three
different mammalian cell lines. siRNAs modiﬁed with
40-thioribonucleosides were well tolerated in both the
sense and antisense strands (13). From our search for
the best modiﬁcation pattern, the modiﬁed siRNAs with
four 40-thioribonucleosides in both ends of the sense
strand and four residues at the 30-end of the antisense
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two target luciferase genes in NIH/3T3, HeLa and MIA
PaCa-2 cell lines (14). These successful results prompted
us to develop a new siRNA molecule possessing a hybrid
type of chemically modiﬁed nucleoside based on 20-OMe
and 40-thioribonucleosides (Figure 1).
We have already developed a synthesis of
20-OMe-40-thioribonucleoside and examined the physical
and physiological properties of fully 20-OMe-40-thioribo
nucleoside modiﬁed RNAs, that is, 20-OMe-40-thioRNAs
(17). In its hybridization property, 20-OMe-40-thioRNA
preferred RNA as a complementary partner rather than
DNA in duplex formation. In addition, an investigation of
their stability revealed that 20-OMe-40-thioRNA was ex-
tremely stable in 50% human plasma (t1/2=1631min)
compared with 20-OMeRNA (t1/2=451min), 20-FRNA
(t1/2=53min) and 40-thioRNA (t1/2=187min). From
these results, we expected 20-OMe-40-thioribonucleoside
modiﬁed siRNA to be thermally stable in duplex forma-
tion and quite stable in biological ﬂuids as well as in
cellular compartments, which make them ideally suitable
for therapeutic applications. In this study, we investigated
the potency and duration of the gene-silencing activity of
siRNAs modiﬁed with 20-OMe-40-thioribonucleosides.
MATERIALS AND METHODS
Oligonucleotides
The chemically modiﬁed oligonucleotides used in this
study were synthesized on an Applied Biosystem 3400
DNA synthesizer as described previously (17). Brieﬂy,
each of phosphoramidite units was used at concentration
of 0.1M in dry acetonitrile, and the coupling time was
extended to 10min for each step. After cleavage and
de-protection, RNAs were puriﬁed by reversed-phase
high performance liquid chromatography (C18). The ana-
lytical data of the synthesized oligonucleotides are
summarized in Supplementary Tables S1 and S2.
Unmodiﬁed (UM) oligonucleotides were purchased from
Hokkaido System Science Co., Ltd. For preparation of
duplexes, sense- and antisense-strand oligonucleotides
(150mM each) were mixed together in an annealing
buffer (100mM potassium acetate, 30mM HEPES–KOH
at pH 7.4, 2mM magnesium acetate) and incubated for
3min at 90 C then cooled gradually to room temperature.
The siRNAs used in this study consisted of a 21-nt with a
2-nt overhang at the 30-end of each strand (luc siRNA:
sense 50-GCGCUGCUGGUGCCAACCCtt-30, antisense
50-GGGUUGGCACCAGCAGCGCtt-30; scrambled siR
NA: sense 50-ACCGACUAGGGGCGUCGCGtt-30, anti-
sense 50-CGCGACGCCCCUAGUCGGUtt-30).
Cell culture
HeLa cells stably expressing luciferase (HeLa-luc) were
cultured at 37 C under 5% CO2 in Dulbecco’s modiﬁed
Eagle’s medium (DMEM, Gibco) supplemented with
10% fetal bovine serum (FBS), 100units/ml penicillin,
100mg/ml streptomycin and 0.4mg/ml G418, as described
previously (18). Cells were regularly passaged to
maintain exponential growth.
Preparation of multifunctional envelop-type nano device
A Multifunctional Envelop-type Nano Device (MEND)
was used as a transfection reagent and was prepared as
described previously (19). SiRNA (0.1mg/ml) was mixed
with STR-R8 (0.1mg/ml at a nitrogen/phosphate ratio of
1.05) in 250ml of HEPES buffer (pH 7.4). A lipid ﬁlm was
formed by evaporation of the chloroform solution contain-
ing 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP),
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)
and cholesterol (125nmol total lipids in a 3:4:3 molar
ratio). The lipid ﬁlms for the modiﬁed MENDs were
prepared by evaporation. The resulting lipid ﬁlm was then
incubated for 10min at room temperature to hydrate the
lipids. The lipid ﬁlm was sonicated for  1 min in a
bath-type sonicator, followed by sonication for 10min
with a probe sonicator. The siRNA/STR-R8 complex was
applied to the lipid ﬁlm. The average diameter and the
z-potential of the condensed siRNA and MENDs were
determined using a Zetasizer Nano ZS ZEN3600
(MALVERN Instrument, Worchestershire, UK).
Luciferase reporter assay
HeLa-luc cells were seeded in a 24-well plate (4 10
4 cells/
500ml per well) in DMEM at 70% conﬂuency for 24h
prior to transfection. siRNAs formulated with MEND
were applied to each well in a total volume of 250ml
Opti-MEM I (Invitrogen). After 3h of incubation at
37 C, 750ml of culture medium containing 10% serum
was added to the cells, followed by incubation at 37 C.
For the time-course experiment, multiple parallel cultures
were maintained for 9 days by serial passage on alternate
days without additional treatment. The cells were washed
with 0.5ml PBS and lysed with reporter lysis buffer
(Promega). Luciferase activity in the cell lysate was
measured using luminometer (Luminescencer-PSN,
ATTO). The protein concentration was determined using
a BCA Protein Assay Kit (Thermo Fisher Scientiﬁc).
Luciferase activity was expressed as relative light units
(RLU) per milligram of protein. Data points represent
the ratio of the average luciferase signal intensity from
triplicate wells receiving anti-luciferase siRNA and
scrambled siRNA. The scrambled siRNA used in this
study had no effect on luciferase expression level by com-
parison with untreated cells. All experiments were per-
formed in triplicate and data shows mean values from at
least three assays.
Figure 1. Structure of 20-OMe-40-thioribonucleoside.
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According to the report of Takahashi et al. (20), the area
under the curve of the inhibitory effect (AUCIE) and the
mean response time of the inhibitory effect (MRTIE)








where RGEI represents the ratio of inhibition of gene
expression.
Stability of siRNAs in 50% mouse serum
Each sense strand of siRNA labeled with
32P at the 50-end
(5pmol) was mixed with the corresponding unlabeled
sense strand (20pmol) and antisense strand (30pmol).
The labeled siRNA duplex was prepared by annealing in
HEPES buffer (pH 7.4) containing 100mM potassium
acetate and 2mM magnesium acetate. The siRNA was
incubated in HEPES buffer (pH 7.4, 20ml) containing
50% mouse serum at 37 C. At appropriate periods, 2ml
aliquots of the reaction mixture were added to 8mlo f
50mM EDTA, and the mixtures were frozen immediately
in liquid nitrogen. After the ﬁnal sample was taken, all the
samples were then dissolved on ice and extracted with
phenol and chloroform. The extracts were mixed with
the loading buffer (1  TBE, 10% glycerol, 0.05%
bromophenol blue, 0.05% xylene cyanol) and analyzed
by electrophoresis on native 15% PAGE. Radioactive
densities of the remaining full-length siRNAs were
visualized and measured by a Bio-imaging analyzer (Bas
2500, Fuji Co., Ltd).
Quantiﬁcation of siRNA in HeLa-luc cells
SiRNAs formulated with MEND (120nM) were trans-
fected into HeLa-luc cells. At the indicated days, cells
were trypsinized and pelleted by centrifugation. The cell
pellets were resuspended in 0.25% Triton X-100 in
phosphate-buffered saline (PBS, 500ml) and heated at
95 C for 10min, then immediately cooled on ice for
10min. The lysates were centrifuged at 20000g for
20min at 4 C and the supernatants were put into a new
tube and kept at  80 C. Reverse transcription reactions
were performed using a TaqMan MicroRNA RT kit
(Applied Biosystems). The lysates were heated at 95 C
for 10min, and aliquots of each hot sample were directly
added into the RT reaction (30min, 16 C, 30min, 42 C,
5min, 85 C). Quantitative PCR reactions were performed
using TaqMan PCR kit (TaqMan probe, forward primer,
reverse primer and TaqMan Universal PCR Master Mix)
on MX3005P QPCR System (Agilent Technologies). All
experiments were performed in triplicate and data shows
mean values from at least three assays.
RESULTS AND DISCUSSION
Optimization of modiﬁcation patterns
We ﬁrst optimized modiﬁcation patterns of siRNA
directed against ﬁreﬂy luciferase. In our previous study,
we found that modiﬁed siRNAs, which have four residues
of the 40-thioribonucleoside unit on both ends of the sense
strand and four 40-thioribonucleosides on the 30-end of the
antisense strand, or four residues on both ends of the sense
strand and two residues on both ends of the antisense
strand (modiﬁcation similar to SM1 and SM2 in
Table 1), exhibited potent RNAi activity. Incorporation
of more 40-thioribonucleosides in the siRNAs resulted in a
decrease in RNAi activity. Therefore, we decided to
prepare SM1 and SM2, which have similar modiﬁcation
patterns as those of the best for 40-thioribonucleoside
modiﬁed siRNAs. We also prepared SM3–SM6
(Table 1), whose antisense strands were UM. Since it is
well known that nuclease-resistant chemical modiﬁcations
at the RISC cleavage site of an siRNA sense strand
(between positions 9 and 10) impaired its gene-silencing
activity (13,21), we avoided introducing the modiﬁcations
adjacent to this cleavage site.
Each siRNA was transfected into HeLa cells, which
constitutively express the luciferase gene (HeLa-luc
cells), at a 120nM concentration using MEND (19),
which was developed for use as an efﬁcient non-viral
system for the delivery of nucleic acids. The average diam-
eters and z-potentials of the MENDs containing the
siRNAs used in this study were  120nm and  30mV,
respectively, and there were no obvious differences in the
size and potential of the MEND containing either UM or
modiﬁed siRNAs. Since the transfection efﬁciency of
siRNA into the cell may also inﬂuence the duration of
activity, we examined the transfection efﬁciency of the
MEND and found that it was comparable to that of the
commercially available Lipofectamine 2000 (the results
are shown in the Supplementary Figure S1). We also con-
ﬁrmed that the transfection of both UM and chemically
modiﬁed siRNA seemed to have no effect on cell viability
and cell division rate. To assess whether the





















Upper case letters represent ribonucleotides; lower case letters represent
20-deoxyribonucleotides; underlined bold italics are 20-OMe-40-thiori
bonucleotides; underlined are 20-OMe; 40-thioribonucleotides are in
italics.
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sides affected RNAi activity in HeLa-luc cells, we
carried out luciferase reporter assays at designated hours
after transfection of siRNAs, and the resulting RNAi
activities are shown in Figure 2. The UM siRNA
showed high potency and suppressed the luciferase gene
expression by 74% 1 day after the transfection (Day 1).
Unlike the modiﬁcation by 40-thioribonucleosides, the
modiﬁcation by 20-OMe-40-thioribonucleosides on both
the sense and antisense strand (SM1 and SM2) resulted
in reduction of RNAi activity. When the antisense strand
was unmodiﬁed, the RNAi activity was restored by >60%
(SM3–6). Thus, SM3–SM5, which have four consecutive
20-OMe-40-thioribonucleosides at the 50-end of the sense
strand but a different number of consecutive residues at
the 30-end of the sense strand (4, 2 and 0 residues, respect-
ively), all showed similar RNAi activity (60–65%). Among
the siRNAs examined, the best potency was observed in
SM6, which has three consecutive 20-OMe-40-thioribon
ucleosides at both ends of the sense strand, with a
higher RNAi activity (79%) than that of UM (74%).
It is worth noting that at Day 5 all the modiﬁed siRNAs
had higher RNAi activity than UM. In particular, SM6
still had higher RNAi activity at Day 5, only a 10%
decrease from Day 1, whereas UM showed less than
one-third of the Day 1 RNAi activity at Day 5. The
results indicated that the siRNAs modiﬁed with
20-OMe-40-thioribonucleosides enhanced the duration of
gene-silencing activity.
Detailed study of the duration of RNAi activity
As shown in Figure 2, SM6 appeared to be the most
promising candidate for activity and duration of
gene-silencing; therefore, we carried out more detailed
time-course experiments using SM6. For comparison, we
also synthesized siRNAs modiﬁed with 20-OMe (M6) and
40-thioribonucleoside (S6) with the same modiﬁcation
pattern as SM6, and evaluated the duration of RNAi
activity along with that of UM. As shown in Figure 3,
effective suppression of luciferase expression was
observed in the cells transfected with either unmodiﬁed
or three modiﬁed siRNAs (SM6, M6 and S6) up to
Day 3 with 70–90% RNAi activity. Drastic changes in
their RNAi activities were observed after Day 3. Thus,
UM showed a signiﬁcant decrease in its RNAi activity
at Day 4, while all other modiﬁed siRNAs still maintained
>70% of their RNAi activity. Then, signiﬁcant differences
in the duration of RNAi activity among the three modiﬁed
siRNAs were observed after Day 5. Although S6 still had
comparable RNAi activity compared with that of the
other two modiﬁed siRNAs up to Day 4, the activity
declined sharply in the following days and almost com-
pletely disappeared at Day 7, just as it did with UM.
Meanwhile, SM6 and M6 showed extended duration of
RNAi activity; even at Day 7, these siRNAs still showed
44% and 27% RNAi activity, respectively. These results
suggested that 20-O-methylation appeared to be the major
contributing factor in the duration of the RNAi activity of
SM6. Thus, the rank order of the duration of RNAi
activity was SM6>M6>S6>UM siRNA.
To examine whether the optimized modiﬁcation pattern
can be applicable to other sequences and targets, we chose
an endogenous cancer-related gene, Raf-1. The siRNA
against Raf-1 mRNA (Raf-SM6) having the same modi-
ﬁcation pattern as SM6 was synthesized and evaluated its
potency comparing UM siRNA (Raf-UM) (sequences of
Raf-1 siRNA are shown in Supplementary Table S3). The
siRNAs were transfected into human prostate cancer PC-3
cells at 1, 10, 25nM concentrations, and the relative Raf-1
mRNA levels were assessed by real-time RT–PCR at 24h
after transfection (Supplementary Figure S2). Raf-SM6
efﬁciently reduced Raf-1 mRNA in a dose-dependent
manner with an IC50 value of 3.4nM, which was more
potent than that of Raf-UM (an IC50 value of 4.7nM).
We also examined the duration of Raf-1 mRNA silencing
by Raf-SM6 compared with Raf-UM. The siRNAs were
transfected into PC-3 cells at 100nM concentrations and
measured Raf-1 mRNA levels by real-time RT–PCR at
Figure 2. Relative potency of siRNAs variously modiﬁed with
20-OMe-40-thioribonucleosides. siRNAs were transfected with MEND
into HeLa-luc cells stably expressing luciferase at 120nM concentra-
tions at Day 0 and luciferase reporter assays were performed at Day 1
and Day 5.
Figure 3. Time-course of RNAi activity of UM and modiﬁed (SM6,
M6 and S6) siRNAs. siRNAs were transfected with MEND into
HeLa-luc cells stably expressing luciferase at 120nM concentrations
at Day 0, and luciferase reporter assays were performed at indicated
days.
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showed similar potency and effectively silenced Raf-1
mRNA at Day 2 (Supplementary Figure S3). As was the
case with the results of luciferase reporter assay described
above, Raf-SM6 remained higher silencing activity
compared with Raf-UM at Day 6. These results suggested
that our optimized modiﬁcation pattern by
20-OMe-40-thioribonucleoside modiﬁed siRNA could be
compatible to other siRNA sequences and targets.
We next carried out dose response experiments using
these siRNAs. All siRNAs exhibited RNAi activity in a
dose-dependent manner (dose response curves are shown
in the Supplementary Figure S4) with the IC50 values
summarized in Table 2. At Day 2, no difference was
observed among the siRNAs studied here with an IC50
values of 22.6–29.2nM. In contrast, a signiﬁcant differ-
ence was observed in their RNAi activity on Day 6,
where the IC50 value for UM was 597nM, while that of
SM6 was 118nM, indicating that SM6 was 5-fold more
potent than UM. The RNAi activity of S6 increased mod-
erately with the IC50 value of 555nM, which was similar
to that of UM. The IC50 value of M6 (252nM) was
between SM6 and S6.
We also evaluated the time-course activity quantita-
tively from a kinetic viewpoint. We used the
pharmacokinetic parameters, that is, the area under
the curve of the inhibitory effect (AUCIE) as an index of
the total intensity of RNAi activity and the mean response
time of the inhibitory effect (MRTIE) as an index of its
duration, which were proposed by Takahashi et al. (20).
These parameters can be calculated by simple numerical
integration using time-course experimental data. Table 2
summarizes the AUCIE and MRTIE values of the siRNAs
studied here. Both AUCIE and MRTIE values of all three
modiﬁed siRNAs were higher than those of the UM
siRNA. The AUCIE values of UM and SM6 were
calculated to be 3.37 and 4.99, respectively, indicating
that, in terms of total RNAi potency, SM6 was 1.53-fold
more potent than UM, and 1.1- and 1.44-fold more potent
than M6 and S6, respectively. The MRTIE value of SM6
provided the numerical conﬁrmation of the duration of its
RNAi activity. Thus, SM6 had the highest value
compared to the UM siRNA, M6 and S6. Together,
these parameters provided conﬁrmation that the
20-OMe-40-thioribonucleoside modiﬁcation improved not
only its RNAi activity but also its duration.
Bartlett and Davis examined the duration of RNAi
mediated gene-silencing activity in vitro and reported
that the activity of UM siRNA lasted less than 1 week
at  100nM siRNA concentrations in rapidly dividing
cell lines (22). They also observed that, despite its
nuclease stability, chemically modiﬁed siRNA
(siSTABLEv2, Dharmacon) did not show any signiﬁcant
increase in the duration of RNAi activity relative to the
UM siRNA in HeLa cells (23). They suggested that sta-
bilization of siRNA against nuclease degradation by
chemical modiﬁcation is important in preventing siRNA
degradation in the extracellular environment, such as the
bloodstream. However, once the siRNA has reached the
cytosol of the target cells, it does not offer any advantages
over UM siRNAs with respect to the duration of RNAi
activity. Likewise, Collingwood et al. demonstrated the
duration of the gene-silencing activity using a 20-OMe
modiﬁed Dicer substrate siRNA (a duplex composed of
a 25-mer sense strand and a 27-mer antisense strand)
compared with its UM duplex. As a result, no signiﬁcant
difference in duration of silencing was observed between
the UM and 20-OMe modiﬁed duplexes (24). In contrast to
these reports, the 20-OMe-40-thioribonucleoside modiﬁed
siRNA (SM6) provided a substantial improvement in the
duration of RNAi activity. As described above,
20-OMe-40-thioRNAs showed signiﬁcant stability against
nuclease degradation; therefore, we hypothesized that the
duration effect of the 20-OMe-40-thioribonucleoside
modiﬁed siRNAs might arise from the intracellular stabil-
ity of the duplex.
Intracellular nuclease stability of the siRNA leads to
long-term RNAi activity
Thusfar,awidevarietyofchemicalmodiﬁcationshavebeen
reported to improve the thermal stabilization of siRNA
duplexes and their resistance toward nuclease degradation.
Among them, the 20-OMe modiﬁcation is well known to
increase nuclease resistance without interrupting RNAi
activity (6–8). On the other hand, we and other groups
have found that 40-thioribonucleoside modiﬁed RNAs
have high resistance toward nuclease degradation (15,25).
Furthermore, we noticed that 40-thioribonucleoside
modiﬁed siRNAs showed durable RNAi activity
compared with the corresponding UM siRNAs (13).
Therefore, we next carried out a comparison of nuclease
stability of SM6 and the UM siRNA in 50% freshly
prepared mouse serum (Figure 4, the results of PAGE are
presented in the Supplementary Figure S5). SM6 showed a
5.5-fold higher stability with a half-life of 9.15h compared
withthatofUM,whichgaveahalf-lifeof1.67h.Thus,these
results indicated that the 20-OMe-40-thioribonucleoside
modiﬁcations caused the increase in siRNA stabilization in
mouse serum.
In order to determine whether the
20-OMe-40-thioribonucleoside modiﬁed siRNA actually
remained intact which caused the persistent RNAi
activity in cells, we next set out to quantify the siRNA
in the cells. Recently, Landesman et al. developed a
novel method for quantitating siRNA from cell lines,
tissues and plasma (26). The method, Heating-in-Triton
Table 2. IC50 values and pharmacokinetic data (AUCIE and MRTIE)
of siRNAs
IC50 (nM)
Day 2 Day 6 AUCIE MRTIE
UM 26.6 597 3.37 2.66
SM6 22.6 118 4.99 3.61
M6 26.3 252 4.70 3.41
S6 29.2 555 3.61 2.81
Nucleic Acids Research, 2012,Vol.40, No. 12 5791quantitative reverse transcription PCR (HIT qRT–PCR),
is based on the stem-loop RT–PCR technique and allows
a highly sensitive quantiﬁcation of chemically modiﬁed
siRNAs. By using this method, we estimated the amount
of transfected siRNAs in HeLa-luc cells. Either 120nM of
SM6 or UM was transfected into HeLa-luc cells, and
siRNA concentrations were measured by monitoring the
ampliﬁcation of the antisense strand of each siRNA by
qRT–PCR over 7 days (Figure 5). The amount of SM6
detected at Day 1 was 2.5 times larger than that of UM
siRNA (1.63fmol/10000 cells and 0.64fmol/10000 cells,
respectively), even though there was little difference in
RNAi activity measured by luciferase reporter assay
described above between SM6 and UM siRNA. The dif-
ferences became larger as time passed and more than 20
times the amount of SM6 molecules remained in the
HeLa-luc cells compared to the UM siRNA on Day 7.
We thus concluded that the intracellular stability of the
modiﬁed siRNA caused by its nuclease resistance property
contributed signiﬁcantly to the duration of the RNAi
activity of the 20-OMe-40-thioribonucleoside modiﬁed
siRNA.
In addition to the intracellular stability of siRNA,
several other factors can inﬂuence the duration of RNAi
activity, including rate of cell division (22), siRNA trans-
fection efﬁciency and half-life of the target protein. In
order to better understand the duration of RNAi
activity, we should keep in mind these factors. Chemical
modiﬁcation of siRNA is thought to be an easy way to
alter the property of siRNA and improve the activity and
duration of gene-silencing. With this study, we have suc-
cessfully demonstrated the importance of intracellular sta-
bility of siRNA for duration of RNAi activity.
CONCLUSION
We have evaluated the effect of chemical modiﬁcation of
siRNA using 20-OMe-40-thioribonucleosides on RNAi
activity. Optimization of both the number and position of
20-OMe-40-thioribonucleoside incorporation afforded
modiﬁed siRNAs with more potent and persistent RNAi
activity, where the modiﬁed siRNAs have three residues
each on both ends of the sense strand, compared with the
UM siRNAs. Further investigation of the duration of
RNAi activity revealed that the 20-OMe-40-thioribon
ucleoside modiﬁed siRNAs showed the most persistent
RNAi activity compared with 20-OMe, 40-thioribonu
cleoside modiﬁed and UM siRNAs. The dose-response ex-




Thus far, a number of reports have demonstrated the
long-term RNAi activity of chemically modiﬁed siRNA
both in vitro (9,10,23,27) and in vivo (23,28). However,
the advantages of nuclease-resistant siRNAs inside the
cell cytoplasm remain less well deﬁned. Our studies
revealed that the nuclease resistance of siRNA is a
dominant factor in prolonging gene-silencing activity.
Therefore, the remarkable nuclease resistance of the
20-OMe-40-thioribonucleosde modiﬁcation facilitates the
intracellular stability of siRNA leading to the duration
of RNAi activity.
From a therapeutic viewpoint, this has important impli-
cations. For instance in patients requiring repeated admin-
istration of drugs, it may be beneﬁcial to silence a target
gene for longer time, since long-term treatment often
produces unintended toxicity. Thus, prolonging RNAi
activity is a major consideration for the therapeutic appli-
cation of siRNA. To this aim, we have demonstrated here
the potential advantage and signiﬁcance of the
20-OMe-40-thioribonucleoside modiﬁcation of siRNA,
which leads to long-lasting RNAi activity. Overall, our
data provide valuable insights into the therapeutic appli-
cation of chemically modiﬁed siRNA.
Many questions still remain to be answered before this
technology can be successfully applied to therapeutic use,
such as unintended off-target effects, activation of innate
immune response and target delivery of siRNA. Further
study to address these concerns and problems not only
in vitro but also in vivo using 20-OMe-40-thioribonucleoside
modiﬁed siRNAs are currently under way. Details of these
results will be published elsewhere.
Figure 4. Stability of siRNAs in 50% mouse serum.
Figure 5. Quantiﬁcation of intracellular siRNAs using HIT qRT–PCR.
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